The receptor tyrosine kinase FLT3 (CD135) is not only constitutively activated in about 30% of AML patients, but also regularly expressed on bulk AML cells and LSCs as compared to HSCs. This evidence concerns the gene NTRK1 and acute myeloid leukemia.